Autonomic Nervous System Pharmacology: Neurotransmission, Adrenoceptor Agonists & Cholinomimetics

The autonomic nervous system (ANS) operates largely outside of conscious awareness to regulate visceral physiology and preserve homeostasis. It fine-tunes blood pressure, myocardial performance, gastrointestinal motility, respiratory diameter, pupillary tone, and glandular secretion.

Unlike the hormonal endocrine system, which circulates broad chemical messengers throughout the bloodstream, the autonomic nervous system relies on discrete neural projections, regional ganglia, and localized plexuses to deliver rapid signals directly to specific visceral effectors.

Somatic versus autonomic efferent architecture

The peripheral nervous system divides functionally into voluntary motor control and involuntary visceral regulation. Their anatomical blueprints differ fundamentally in neuron arrangement, myelination, and denervation outcomes:

Autonomic divisions: Sympathetic, parasympathetic, and enteric

The autonomic nervous system splits anatomically and functionally into three primary divisions:

Autonomic dual innervation and physiological exceptions

Most visceral organs receive opposing inputs from both sympathetic and parasympathetic nerves. Final organ activity reflects the algebraic sum of their firing rates. However, several clinically important tissues receive unilateral innervation:

• Exclusively sympathetic targets: Most systemic peripheral blood vessels (vascular resistance is set by varying sympathetic baseline tone), eccrine sweat glands (innervated by sympathetic fibers releasing ACh), splenic capsule smooth muscle, pilomotor muscles of hair follicles, and the adrenal medulla.
• Exclusively parasympathetic targets: Gastric parietal cells, lacrimal glands, and the ciliary muscle of the eye (for accommodation).
• Non-antagonistic exception: Within cardiac atrial muscle, both sympathetic stimulation and parasympathetic activation reduce the effective refractory period (ERP), showing that autonomic inputs are not always purely opposite.

To understand how autonomic drugs work, we must separate conduction (electrical propagation down a single nerve fiber) from transmission (chemical passage of signals across a synaptic cleft).

Axonal conduction mechanics

At rest, the interior of a mammalian axon maintains a resting membrane potential of approximately -70 mV relative to the outside, largely determined by selective potassium permeability via K⁺ leak channels. The active Na⁺/K⁺-ATPase pump maintains this baseline gradient by moving 3 Na⁺ ions outward in exchange for 2 K⁺ ions inward per molecule of ATP consumed.

When an incoming stimulus depolarizes the axon to its critical firing threshold, voltage-gated sodium channels open rapidly, allowing Na⁺ to surge into the cytoplasm along its electrochemical gradient. Voltage-gated sodium channels then inactivate, while delayed-rectifier potassium channels open to let K⁺ flow outward. This repolarizes the membrane back toward its resting potential.

Steps of chemical junctional transmission

Unlike axonal conduction, junctional transmission crosses the fluid-filled synaptic gap using chemical messengers. The process moves through five sequential steps:

1. Transmitter synthesis: Small-molecule neurotransmitters are synthesized locally in the nerve terminal cytoplasm by dedicated enzymes.
2. Vesicular storage: Specialized proton-antiporter proteins pump synthesized neurotransmitters into storage vesicles, protecting them from cytoplasmic degradation.
3. Depolarization-secretion coupling: An arriving action potential depolarizes the presynaptic terminal, opening voltage-gated N-type calcium (Ca²⁺) channels. Entering calcium binds to vesicular sensor proteins (synaptotagmin), triggering the SNARE complex (synaptobrevin on the vesicle; syntaxin and SNAP-25 on the terminal membrane) to fuse the vesicle with the cell membrane and release its contents by exocytosis.
4. Receptor activation: The released transmitter diffuses across the narrow synaptic gap (~20–40 nm) and binds to postjunctional receptors, generating either an excitatory postsynaptic potential (EPSP) or an inhibitory postsynaptic potential (IPSP).
5. Termination of action: Signal transmission ends rapidly through enzymatic breakdown, high-affinity reuptake back into the nerve terminal, or diffusion away from the synapse.

Acetylcholine (ACh) serves as the primary neurotransmitter across all preganglionic autonomic fibers, parasympathetic postganglionic terminals, sympathetic fibers to sweat glands, the somatic neuromuscular junction, and central cognitive pathways.

Synthesis, storage, and release mechanics

The life cycle of acetylcholine involves four tightly linked steps:

• Choline transport (The rate-limiting bottleneck): Extracellular choline is taken up into the presynaptic cytoplasm by a high-affinity, sodium-dependent membrane transporter (Carrier A). This step governs the overall rate of ACh synthesis. The research drug hemicholinium competitively blocks this transporter, gradually emptying the terminal of acetylcholine.
• Enzymatic acetylation: In the cytoplasm, choline acetyltransferase (ChAT) transfers an acetyl group from mitochondrial acetyl-CoA onto choline, generating acetylcholine.
• Vesicular packaging: Acetylcholine is pumped into synaptic vesicles (each holding 1,000 to 50,000 transmitter molecules) by the vesicular acetylcholine transporter (VAT; Carrier B), an antiporter that exchanges luminal protons for cytoplasmic ACh. The experimental compound vesamicol blocks this transporter, preventing vesicle refilling.
• Calcium-dependent exocytosis: Inflowing calcium destabilizes vesicle moorings, driving SNARE-mediated fusion with the presynaptic membrane to release acetylcholine into the cleft.

Termination: Acetylcholinesterase versus butyrylcholinesterase

Acetylcholine does not rely on presynaptic reuptake to end its signal. Instead, it is cleaved within milliseconds by extracellular esterase enzymes:

Receptors that respond to acetylcholine fall into two distinct families based on their structure and downstream signaling:

Muscarinic receptors (GPCRs)

Muscarinic receptors are seven-transmembrane G-protein-coupled receptors. They respond selectively to the mushroom alkaloid muscarine and are blocked competitively by atropine. Five distinct subtypes (M₁ to M₅) exist, each with a characteristic tissue distribution:

Nicotinic receptors (Ligand-gated ion channels)

Nicotinic receptors are pentameric ligand-gated ion channels. Two acetylcholine molecules bind to their alpha subunits, triggering a conformational shift that opens a central pore for Na⁺ and Ca²⁺ entry and K⁺ exit. This causes rapid depolarization within milliseconds:

Direct-acting cholinomimetics bind directly to cholinoceptors, mimicking the actions of acetylcholine. They fall chemically into synthetic choline esters and naturally occurring cholinomimetic plant alkaloids:

Pilocarpine in glaucoma

Glaucoma is characterized by elevated intraocular pressure (IOP) that damages optic nerve axons. Pilocarpine lowers IOP through direct muscarinic actions within the anterior chamber of the eye:

• Contraction of the pupillary sphincter muscle: Produces rapid pupillary constriction (miosis). In acute angle-closure glaucoma, miosis pulls the peripheral iris away from the trabecular meshwork, opening the closed iridocorneal angle.
• Contraction of the ciliary muscle: Puts tension on the scleral spur, stretching the pores of the trabecular meshwork. This promotes outflow of aqueous humor into the canal of Schlemm, steadily reducing intraocular pressure.
• Spasm of accommodation: Because the ciliary muscle stays contracted, the lens relaxes into a rounded shape, fixing vision for near objects. This produces temporary myopia and brow ache, which are classic adverse effects in younger patients.

Anticholinesterases act indirectly by inhibiting acetylcholinesterase. By blocking this enzyme, they prevent the normal breakdown of endogenous acetylcholine, allowing it to accumulate at cholinergic synapses throughout the body.

Structure and catalytic mechanics of acetylcholinesterase

The catalytic pocket of acetylcholinesterase features two primary interaction sites:

• The anionic subsite: Contains an essential tryptophan residue that coordinates the positively charged quaternary nitrogen of acetylcholine through electrostatic attraction.
• The esteratic subsite: Contains a catalytic triad of serine, histidine, and glutamate. Serine attacks the ester carbonyl carbon of acetylcholine, releasing free choline and leaving an acetylated serine. Water rapidly hydrolyzes this acetyl-enzyme intermediate within microseconds, regenerating the active enzyme and releasing acetic acid.

Mechanistic classes of anticholinesterases

Anticholinesterase drugs differ in how they bind to these active sites, which determines their duration of action:

Physostigmine versus neostigmine

The choice between physostigmine and neostigmine hinges on their chemical structures, lipid solubility, and ability to cross the blood-brain barrier:

Excessive cholinergic stimulation leads to acute toxic crises that require rapid clinical recognition and specific antidotes.

Myasthenia gravis: Pathophysiology and crisis differentiation

Myasthenia gravis is an acquired autoimmune disorder caused by autoantibodies directed against postjunctional N_M nicotinic receptors at the skeletal motor endplate. These antibodies cross-link and internalize the receptors, accelerating their destruction and reducing functional receptor counts by up to 70%. Patients present with fluctuating muscle weakness that worsens with exercise, typically starting as ptosis and diplopia before progressing to difficulty chewing, swallowing, and breathing.

When a patient with myasthenia gravis develops acute respiratory failure and severe generalized weakness, two opposing clinical conditions must be distinguished:

Organophosphate poisoning

Organophosphate exposure—from agricultural pesticides or chemical nerve agents—causes widespread acetylcholine accumulation across muscarinic, nicotinic, and central synapses:

Antidotal pharmacotherapy: Atropine and oxime reactivators

Managing organophosphate poisoning requires immediate supportive care alongside two complementary antidotes:

• Atropine sulfate: Competitively blocks muscarinic receptors throughout the body. It reverses life-threatening bronchospasm, dries up excessive tracheobronchial secretions, and relieves bradycardia. It is given as an initial dose of 2 mg IV, doubled every 5 to 10 minutes until full "atropinization" is achieved (clear lungs, dry mouth, heart rate > 80 bpm, and mydriasis). Patients may need several hundred milligrams over several days. Note: Atropine has no effect on nicotinic receptors and cannot reverse diaphragm paralysis.
• Cholinesterase reactivators (Oximes: Pralidoxime / 2-PAM, Obidoxime): Oximes have a high affinity for the phosphorus atom on the organophosphate molecule. The quaternary nitrogen of pralidoxime binds to the anionic site of acetylcholinesterase, positioning its reactive oxime group (=N-OH) next to the phosphorylated serine. The oxime attacks the phosphorus atom, forming an oxime-phosphonate complex that detaches, regenerating the active enzyme.
• The aging window: Oximes must be given early—ideally within 24 to 48 hours of exposure. Once aging occurs, the chemical bond is permanent, and oximes can no longer reactivate the enzyme.
• Contraindication in carbamate poisoning: Pralidoxime should not be used in carbamate poisoning (e.g., carbaryl, propoxur). Carbamylated enzymes regenerate spontaneously within hours, and oximes can worsen carbamate toxicity by inhibiting acetylcholinesterase themselves.

Mushroom poisoning classifications

Mushroom toxicity varies widely depending on the underlying species and chemical toxins involved:

The adrenergic nervous system uses norepinephrine (noradrenaline) as its primary postganglionic transmitter, along with epinephrine and dopamine, to regulate vascular resistance, cardiac performance, and metabolic responses.

Catecholamine biosynthesis pathway

Biosynthesis takes place within adrenergic nerve varicosities and adrenal chromaffin cells through four linked enzymatic steps:

1. Tyrosine hydroxylation (The rate-limiting step): Circulating L-tyrosine is actively transported into the neuron terminal. Tyrosine hydroxylase (TH) adds a hydroxyl group to the aromatic ring, forming dihydroxyphenylalanine (L-DOPA). This is the key regulatory step in catecholamine synthesis. The drug α-methyltyrosine (metyrosine) competitively inhibits this enzyme, which can be useful in treating inoperable pheochromocytoma.
2. DOPA decarboxylation: The cytosolic enzyme DOPA decarboxylase removes the carboxyl group from L-DOPA, converting it into dopamine.
3. Vesicular storage and β-hydroxylation: Dopamine is actively pumped into storage vesicles by the vesicular monoamine transporter (VMAT-2). Inside the vesicle, dopamine β-hydroxylase (DBH) adds a hydroxyl group to the β-carbon, forming norepinephrine. This vesicular location protects the newly made transmitter from degradation by cytosolic enzymes.
4. N-methylation (Adrenal medulla): In the adrenal medulla, norepinephrine diffuses out of storage granules into the cytosol. The enzyme phenylethanolamine N-methyltransferase (PNMT)—whose expression is maintained by high local cortisol levels from the adrenal cortex—transfers a methyl group onto the amine nitrogen to form epinephrine. Epinephrine is then pumped back into chromaffin granules for storage.

Presynaptic targets and transport mechanisms

Several clinical drugs work by targeting presynaptic storage, reuptake, or release rather than the receptors themselves:

• Vesicular monoamine transporter (VMAT-2) inhibition: The plant alkaloid reserpine binds irreversibly to VMAT, blocking monoamine entry into vesicles. Unprotected dopamine and norepinephrine accumulate in the cytosol, where monoamine oxidase (MAO) breaks them down. This gradually depletes catecholamine stores, historically providing an antihypertensive effect but often causing severe depression.
• Norepinephrine transporter (NET / Uptake 1) inhibition: Synaptic signals are ended when NET pumps norepinephrine back into the presynaptic terminal (clearing ~80% of released transmitter). Cocaine and tricyclic antidepressants (TCAs) block NET, preventing norepinephrine reuptake and prolonging its action on postsynaptic receptors. This contributes to cocaine's acute cardiovascular toxicity (severe tachycardia, hypertension, and vasospasm).
• Reversed vesicular displacement: Amphetamines, ephedrine, and tyramine act as substrates for NET, entering the presynaptic cytoplasm. Once inside, they enter storage vesicles via VMAT, displacing stored norepinephrine into the cytoplasm. This raises cytosolic norepinephrine levels, which forces NET to run in reverse, pumping flood of norepinephrine out into the synapse independently of action potentials or calcium.

Adrenoceptors are G-protein-coupled receptors divided into two major families, α and β, each containing multiple subtypes with distinct tissue distributions and second messenger cascades:

Adrenergic agonists are categorized by their chemical structures, receptor selectivities, and direct versus indirect mechanisms of action.

Catecholamines versus non-catecholamines

A catecholamine possesses a benzene ring with two adjacent hydroxyl groups (a catechol nucleus) and an amine side chain:

Classification by mechanism of action

Sympathomimetics act through three primary mechanisms:

1. Direct-acting agonists: Bind directly to adrenergic receptors to stimulate intracellular signaling cascades. Examples include epinephrine, norepinephrine, dopamine, isoproterenol, phenylephrine, dobutamine, salbutamol, and clonidine.
2. Indirect-acting agonists: Increase synaptic norepinephrine concentrations without directly activating adrenoceptors:
   • Releasing agents: Displace stored norepinephrine from vesicles into the synapse (e.g., amphetamine, methamphetamine, tyramine).
   • Reuptake inhibitors: Inhibit the NET transporter to block transmitter clearance (e.g., cocaine, tricyclic antidepressants).
3. Mixed-acting agonists: Simultaneously stimulate postsynaptic receptors directly while displacing stored norepinephrine from presynaptic vesicles (e.g., ephedrine, pseudoephedrine, metaraminol). Repeated dosing of indirect or mixed-acting agents can cause rapid tolerance (tachyphylaxis) as presynaptic stores are depleted.

Hemodynamic comparison: Epinephrine, norepinephrine, and isoproterenol

The cardiovascular responses to catecholamine infusions depend on the balance of their α and β receptor actions:

Adrenergic agonists are used across multiple organ systems for emergency stabilization, chronic disease management, and surgical procedures: